[Development and clinical translation of in vivo chimeric antigen receptor-T cell therapy].

Chimeric antigen receptor-T cell (CAR-T) therapy has achieved remarkable efficacy, however, the complex process and high treatment costs largely limit the clinical application of conventional CAR-T therapy. With the advancement of biotechnology, in vivo CAR-T therapy is steadily moving from the laboratory into the clinical practice. This thesis systematically synthesizes the delivery vehicles for in vivo CAR-T therapy, including viral vector system [lentiviral vectors, adeno-associated virus (AAV) vectors] and non-viral vector system [polymeric nanoparticles, lipid nanoparticles (LNP), and other delivery vectors]. Meanwhile, focusing on the design strategies and clinical trials, it summarizes clinical practices of in vivo CAR-T therapy at home and abroad, and discuss the existing challenges and future prospects in combination with the latest data, aiming to facilitate its development and clinical translation in China.